Web of Science: 26 cites, Scopus: 23 cites, Google Scholar: cites,
HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells : a two-site study
Grau Vorster, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Laitinen, Anita (Finnish Red Cross Blood Service. Advanced Cell Therapy Centre)
Nystedt, Johanna (Finnish Red Cross Blood Service. Advanced Cell Therapy Centre)
Vives Armengol, Joaquim (Universitat Autònoma de Barcelona. Departament de Medicina)
Hospital Universitari Vall d'Hebron
Universitat Autònoma de Barcelona

Data: 2019
Resum: Background: Contrary to the minimal criteria proposed by the International Society for Cell and Gene Therapy for defining multipotent mesenchymal stromal cells (MSC), human leukocyte antigen (HLA)-DR expression is largely unpredictable in ex vivo-expanded clinical-grade cultures. Although activation of MSC in culture does not appear to affect their functionality, a large study investigating the impact of HLA-DR expression on cell identity and potency is still missing in the literature. Methods: A retrospective analysis of HLA-DR expression in 130 clinical batches of bone marrow (BM)-MSC from two independent Good Manufacturing Practice-compliant production facilities was performed in order to identify the consequences on critical quality attributes as well as potential activation cues and dynamics of MSC activation in culture. Results: HLA-DR cells in culture were confirmed to maintain fibroblastic morphology, mesenchymal phenotype identity, multipotency in vitro, and immunomodulatory capacity. Interestingly, the use of either human sera or platelet lysate supplements resulted in similar results. Conclusions: HLA-DR expression should be considered informative rather than as a criterion to define MSC. Further work is still required to understand the impact of HLA-DR expression in the context of product specifications on BM-MSC qualities for clinical use in specific indications.
Ajuts: Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR719
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR71
Nota: Altres ajuts: BST is a member of the Spanish Cell Therapy Network (Red de Terapia Celular, TerCel, expedient No. RD16/0011/0028), awarded by the Generalitat de Catalunya as Consolidated Research Group and developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian ERDF operational program (European Regional Development Fund) 2014-2020.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article ; recerca ; Versió publicada
Matèria: Multipotent mesenchymal stromal cell ; Potency ; Identity ; HLA-DR ; Cellular therapy ; Cell culture ; Quality compliance
Publicat a: Stem cell research & therapy, Vol. 10 Núm. 1 (13 2019) , p. 164, ISSN 1757-6512

DOI: 10.1186/s13287-019-1279-9
PMID: 31196185


8 p, 3.4 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2020-06-03, darrera modificació el 2022-04-10



   Favorit i Compartir